Phaseline

Targets › EFNB2

EFNB2 (Ephrin-B2): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 1; Oncology, Immunology; next expected readout Dec 2028.

Cell surface transmembrane ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. (UniProt, P52799)

Open in Phaseline: the race on EFNB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mediar TherapeuticsMTX-474
anti-EphrinB2 monoclonal antibody
EFNB2Phase 2Diffuse Cutaneous Systemic SclerosisDec 2028
Vasgene TherapeuticsSEphB4-HSA
Ephrin-B2 inhibitor
EFNB2Phase 2Muscle-Invasive Bladder Carcinoma; Stage IV Bladder Urothelial Carcinoma; Head and Neck Squamous Cell CarcinomaSep 2029

Conditions

Muscle-Invasive Bladder Carcinoma (1) Stage IV Bladder Urothelial Carcinoma (1) Head and Neck Squamous Cell Carcinoma (1) Diffuse Cutaneous Systemic Sclerosis (1)

Modalities

mixed (1), protein or peptide (1)

Companies

Vasgene Therapeutics (1) Mediar Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.